IBDEI0V5 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15362,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,15363,0)
 ;;=V10.82^^89^905^40
 ;;^UTILITY(U,$J,358.3,15363,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15363,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,15363,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,15363,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,15364,0)
 ;;=V10.62^^89^905^43
 ;;^UTILITY(U,$J,358.3,15364,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15364,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,15364,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,15364,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,15365,0)
 ;;=V10.63^^89^905^41
 ;;^UTILITY(U,$J,358.3,15365,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15365,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,15365,1,5,0)
 ;;=5^Hx of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,15365,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,15366,0)
 ;;=V11.2^^89^905^32
 ;;^UTILITY(U,$J,358.3,15366,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15366,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,15366,1,5,0)
 ;;=5^Hx of Dysthymia
 ;;^UTILITY(U,$J,358.3,15366,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,15367,0)
 ;;=V15.81^^89^905^60
 ;;^UTILITY(U,$J,358.3,15367,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15367,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,15367,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,15367,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,15368,0)
 ;;=V10.43^^89^905^44
 ;;^UTILITY(U,$J,358.3,15368,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15368,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,15368,1,5,0)
 ;;=5^Hx of Ovarian CA
 ;;^UTILITY(U,$J,358.3,15368,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,15369,0)
 ;;=V12.71^^89^905^45
 ;;^UTILITY(U,$J,358.3,15369,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15369,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,15369,1,5,0)
 ;;=5^Hx of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,15369,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,15370,0)
 ;;=V10.46^^89^905^48
 ;;^UTILITY(U,$J,358.3,15370,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15370,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,15370,1,5,0)
 ;;=5^Hx of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,15370,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,15371,0)
 ;;=V11.0^^89^905^50
 ;;^UTILITY(U,$J,358.3,15371,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15371,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,15371,1,5,0)
 ;;=5^Hx of Schizophrenia
 ;;^UTILITY(U,$J,358.3,15371,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,15372,0)
 ;;=V10.83^^89^905^51
 ;;^UTILITY(U,$J,358.3,15372,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15372,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,15372,1,5,0)
 ;;=5^Hx of Skin Cancer (Non-Melanoma)
 ;;^UTILITY(U,$J,358.3,15372,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,15373,0)
 ;;=V15.1^^89^905^53
 ;;^UTILITY(U,$J,358.3,15373,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15373,1,4,0)
 ;;=4^V15.1
 ;;^UTILITY(U,$J,358.3,15373,1,5,0)
 ;;=5^Hx of Surgery To Heart And Great Vessels
 ;;^UTILITY(U,$J,358.3,15373,2)
 ;;=^295283
 ;;^UTILITY(U,$J,358.3,15374,0)
 ;;=V15.82^^89^905^57
 ;;^UTILITY(U,$J,358.3,15374,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15374,1,4,0)
 ;;=4^V15.82
 ;;^UTILITY(U,$J,358.3,15374,1,5,0)
 ;;=5^Hx of Tobacco Use (not current)
 ;;^UTILITY(U,$J,358.3,15374,2)
 ;;=Hx of Tobacco Use (not current)^303405
 ;;^UTILITY(U,$J,358.3,15375,0)
 ;;=V12.01^^89^905^54
 ;;^UTILITY(U,$J,358.3,15375,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15375,1,4,0)
 ;;=4^V12.01
